Reuters
08 Dec 2025, 12:32 UTC · 46w ago
Verdict
Headline takes no side. We score RXRX +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
2 claims · scored −1 bearish … +1 bullish
Recursion Pharma's experimental oral drug reduced abnormal colon growths in patients with a rare genetic condition.
More positive than 92% of claims this week
The drug discovery process for this candidate utilized the company's artificial intelligence platform.
Continue reading
5 related stories
More positive than 62% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Positive clinical results for an experimental drug targeting rare genetic conditions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2h ago
−14.4%
Price is moving against the score
$4.03 vs $4.71 close before publication (Dec 5) · not market-adjusted
RXRX chart →
